For the first time in a decade, the American Heart Association and American Stroke Association issued new recommendations for preventing strokes.

A recent study found significant reductions in opioid overdose and alcohol misuse among people taking GLP-1 drugs like Ozempic.

A new study suggests that medications like Ozempic could help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.

What this means is that by changing only one hormone, “suddenly you change your entire relationship with food”, says Prof Giles Yeo, an obesity scientist at the University of Cambridge. And that has all sorts of implications for the way we think about obesity.

Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence that the drugs yield health benefits beyond diabetes and weight loss.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will study the impact of a weight-loss drug on work and productivity.

Both Wegovy and Mounjaro are given as weekly injections via pre-filled pens that can be self-administered into the upper arm, thigh or stomach. They work as an appetite suppressant by mimicking a hormone called glucagon-like peptide-1 (GLP-1).

One of the most prominent medical developments in recent years has been the emergence of a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The best known of these drugs is Ozempic,